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Abstract
Genotype imputation is often used in the meta-analysis of genome-wide association studies (GWAS), for combining data
from different studies and/or genotyping platforms, in order to improve the ability for detecting disease variants with small
to moderate effects. However, how genotype imputation affects the performance of the meta-analysis of GWAS is largely
unknown. In this study, we investigated the effects of genotype imputation on the performance of meta-analysis through
simulations based on empirical data from the Framingham Heart Study. We found that when fix-effects models were used,
considerable between-study heterogeneity was detected when causal variants were typed in only some but not all
individual studies, resulting in up to ,25% reduction of detection power. For certain situations, the power of the meta-
analysis can be even less than that of individual studies. Additional analyses showed that the detection power was slightly
improved when between-study heterogeneity was partially controlled through the random-effects model, relative to that of
the fixed-effects model. Our study may aid in the planning, data analysis, and interpretation of GWAS meta-analysis results
when genotype imputation is necessary.
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Introduction
Genome-wide association studies (GWA studies or GWAS) using
high-throughput genotyping data are a powerful tool and are of a
great help in identifying susceptibility loci for human complex traits
and common diseases [1–4]. However as most of these susceptibility
loci have small effects, large sample sizes are usually required for
having sufficient statistical detection powers. Such sample size
requirement can be beyond the capacity of a single GWA study.
A partial solution to this issue is meta-analysis, which combines
data from multiple studies of relatively small sample sizes, with the
expectation to detect genes underlying susceptibility loci with
greater power and produce more precise estimation of genetic
effects, and hence to provide more convincing conclusions than
the original individual studies do [5–8]. This strategy has been
applied to and improved our understanding in a number of
common diseases, such as Parkinson’s disease [9], type 2 diabetes
[10–12], bipolar disorder [13], colorectal cancer [14], and
rheumatoid arthritis [15], demonstrating the applicability and
usefulness of meta-analysis of GWAS.
A useful tool in GWAS is imputation, which can provide the
same set of SNPs across individual studies by inferring millions of
untyped/missing SNPs from typed SNPs and based on the known
knowledge such as haplotype structure from HapMap [16].
Imputation can improve the power for GWAS in a single study
[17], and can also be used for meta-analysis of GWAS by
combining data from different studies and/or with different
genotyping platforms. However, imputation is not perfect, and
errors and uncertainty can be introduced in the imputed
genotypes. These issues may consequently affect the detection
power of meta-analysis with imputation, which however has not
been fully investigated. Thus, it is necessary to investigate the
impact of imputation on GWAS, for appropriate planning, data
analysis, and interpretation of meta-analysis of GWAS.
To better assess the usefulness and limitation of the meta-
analyses of GWAS using genotype imputation, several critical
questions need to be answered:
N Does genotype imputation affect (or create) between-study
heterogeneity? If yes, how does this heterogeneity caused by
imputation affect the performance of meta-analysis of GWAS?
N Does imputation-based meta-analysis of GWAS with a much
larger sample size always have greater power than that of
individual component studies with smaller sample sizes?
N What to do in the presence of potential negative impacts of
genotype imputation on the meta-analysis of GWAS?
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sive simulation studies based on the empirical GWAS dataset from
the Framingham Heart Study (FHS). We found that genotype
imputation may cause between-study heterogeneity and reduce
the power of meta-analysis of GWAS. Strategies were proposed to
alleviate this negative impact of genotype imputation on meta-
analysis of GWAS.
Results
Imputation effects on between-study heterogeneity
Data structure such as sample size and simulation parameters
were indicated in Tables 1 and 2 (see the Materials and Methods
section for details). We assessed the impact of genotype imputation
on between-study heterogeneity using two measurements for the
index I2: the mean value of I2 and the average percentage of
simulations with I2.50% (referred as large between-study
heterogeneity [6]). Results were based on 1,000 simulations for
each scenario with various QTL variances and risk increasing
allele frequencies (RAFs) (Fig. 1). Between-study heterogeneity was
almost ignorable for Scenario 1 (SNPs fully genotyped across sub-
samples, Fig. 1 A and B) and Scenario 2 (SNPs fully imputed
across sub-samples, Fig. 1 C and D), with the highest mean I2
below 15% and only limited fraction (,10%) of the simulations
having I2.50% for relatively rare SNPs (RAF between 0.01–
0.05). In contrast, significantly higher mean I2 and higher
percentage of large between-study heterogeneity were observed
in Scenarios 3 and 4 (when SNPs were imputed in one or two sub-
samples, Fig. 1 E–H). For Scenario 3, up to 60 percent of the
simulations showed I2.50%, and the mean I2 values reached 40–
50% for SNPs with RAF1-3. Scenario 4 showed similar level of
between-study heterogeneity to that of Scenario 3. In addition, in
Scenarios 3 and 4, between-study heterogeneity was observed to
increase with a larger variation explained by QTLs, and decrease
with a higher RAF. Therefore, imputation may cause between-
study heterogeneity, especially when imputation was performed in
some but not all of the sub-samples.
Comparison of performance of meta-analysis with and
without genotype imputation
The estimated type-I error rates and the power of meta-analysis
with both fixed-effects model and random-effects model are shown
in Table 3. For Scenarios 1 & 2, which have little between-study
heterogeneity, both fixed-effects and random-effects models had
correct type-I error rates that were below the target level 5%
under all conditions. For Scenarios 3 & 4, under which
considerable between-study heterogeneity existed, random-effects
model still had comparable type-I error rates. The fixed-effects
model however may have inflated type-I error rates, which can be
over 60% greater than that of random-effects model, showing the
need of taking caution in selecting appropriate meta-analysis
strategy.
The power of the meta-analysis was different for various
scenarios (Table 3). In general, the highest power was observed
when causal SNPs were genotyped in all individual component
studies (Scenario 1), followed by the situation when causal SNPs
were imputed in all individual component studies (Scenario 2), and
the lowest power was seen when SNPs were genotyped in some
sub-samples and imputed in the other sub-samples (Scenarios 3 &
4). For the independent populations generated through HAP-
GEN2 [18], Scenario 2 had similar powers as those of Scenarios 3
and 4 (results not shown). When compared between meta-analysis
with fixed-effects model and that with random-effects model, the
power was almost the same for Scenario 1 or Scenario 2. For
Scenarios 3 & 4, meta-analysis using random-effects model
performed slightly better than that using fixed-effects model,
particularly when QTL variance was relatively large. For instance,
when s2
a =2%, a 5–25% power increase was shown for random-
effects model over that for fixed-effects model. These results
indicate that meta-analysis with random-effects model is more
appropriate for GWAS with imputation.
The estimation accuracy of the genetic effects, measured by
mean(^ b b) and SE(^ b b), were different for various scenarios, as shown
in Fig. 2. The mean(^ b b) values were almost equal to the true values
for Scenario 1, and were underestimated for Scenarios 2–4. The
percentages of underestimation were similar across different RAF
intervals. For example, when the simulated mean(^ b b) was
3:76(SE~0:35) within RAF2, the mean(^ b b) was 3:74(SE~0:59)
Table 1. Selection strategy and quality control parameters for sub-population construction.
Samples Selection strategy Sample size No. of SNPs surviving QC
Pre-QC After-QC
Sample 1 Singletons, all unrelated subjects from the 1
st generation (two at most) in each pedigree,
plus married-ins in the 2
nd and the 3
rd generations
2,200 2,023 412,432
Sample 2 One subject from the 2
nd generation in each pedigree 1,071 1,055 416,800
Sample 3 One subject from the 3
rd generation in each pedigree 812 806 417,532
Parameter values for quality control (QC): minor allele frequency .0.01, Hardy-Weinberg equilibrium test p-values.0.0001, sample call-rate .0.90, and SNP call-rate
.0.90.
doi:10.1371/journal.pone.0034486.t001
Table 2. Simulation schemes and parameters.
Genotypes of the causal SNPs
Scenario 1 Directly-typed in all three sub-samples
Scenario 2 Imputed in all three sub-samples
Scenario 3 Imputed in Samples 1 & 2 but typed in Sample 3
Scenario 4 Imputed in Sample 1 but typed in Samples 2 & 3
Range of risk increasing allele frequency (RAF)
RAF1 0.01,RAF#0.05
RAF2 0.05,RAF#0.10
RAF3 0.10,RAF#0.20
RAF4 0.20,RAF#0.50
QTL variation 0.5%,1.0%,1.5% and 2.0%
doi:10.1371/journal.pone.0034486.t002
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for Scenario 3.
Power comparison between imputation-based meta-
analysis and individual association studies
Power comparisons between meta-analysis and individual
association analyses were conducted and were partially shown in
Fig. 3. As indicated previously, meta-analysis with causal SNPs
typed (Scenario 1) or imputed (Scenario 2) across sub-samples had
higher power. When all causal SNPs were typed in Sample 1, the
power of the analyses in individual Sample 1 was compatible with
that of Scenarios 1 and 2, and was higher than that of Scenarios 3
and 4. Moreover, the power of the analyses in individual Sample 1
was still mostly higher than that of Scenarios 3 and 4, even when
causal SNPs were imputed in Sample 1. These results illustrate the
importance of taking cautions when applying meta-analysis with
genotype imputation to GWAS, as the power of the analyses in
individual samples may not be necessarily lower than that of the
meta-analysis with genotype imputation.
Discussion
In this study, we investigated the performance of imputation-
based meta-analysis of GWAS through an empirical GWAS
genotype data. Considerable between-study heterogeneity was
Figure 1. Assessment of between-study heterogeneity under various scenarios. The plots in the left column (A, C, E, G) show the mean
values of I2, and those in the right column (B, D, F, H) show the average percentage of simulations with I2w50% (large between-study
heterogeneity). The plots in rows 1–4 are for scenarios 1–4, respectively. Descriptions of scenarios and RAF’s are given in Table 2, and ‘‘var’’ values
indicate the simulated QTL variance.
doi:10.1371/journal.pone.0034486.g001
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causal variants were typed in some individual studies and imputed
in the others. Specifically, for meta-analysis using fixed-effects
model, the power loss was up to ,25% for situations that causal
genes were genotyped in some but not all individual component
studies, comparing to relatively homogenous situations of typed
causal variants across all individual studies. Notably, for situations
of partially directly-typed causal variants, the power of meta-
analysis may be lower than that of analyses performed in some
individual studies.
An important issue in meta-analysis is the potential existence of
between-study heterogeneity, which can affect the power of the
meta-analysis. In the context of genome-wide association studies,
the between-study heterogeneity can be caused by various factors,
such as the variation of genetic effects across different populations,
incomparable measures of phenotype used in different studies,
and/or the deviation from Hardy–Weinberg equilibrium for SNPs
and population stratification. With the above-mentioned hetero-
geneity-causing factors removed by constructing our sub-samples
from a single population and using the same distribution for
genetic effects across sub-samples, the observed between-study
heterogeneity in our simulated sub-samples will be most likely to
be only due to imputation, indicating another possible source of
between-study heterogeneity for the meta-analysis of GWAS.
Although our study is based on simulations for an empirical data
set, the observations from our study are closely relevant to
practical analyses. An interesting and useful observation is that a
meta-analysis with imputation is not necessarily more powerful
than that of analyses performed in individual samples, as shown in
Fig. 3, especially when imputation was performed in some but not
all individual samples. This may be because the loss of power due
to the introduced uncertainty by imputation is greater than the
gained power by increasing the sample size through meta-analysis.
This observation illustrates the importance of taking cautions in
the application and data interpretations of applying meta-analysis
to GWAS. In addition, we compared the analyses under different
imputation scenarios, one of which is that SNPs are genotyped in
some individual samples, but untyped in other samples. This
situation is not uncommon in practice. For example, when
different genotyping platforms are used for different GWA studies,
many SNPs will be genotyped in some samples for one specific
genotyping platform, and be untyped in other samples with a
different genotyping platform, requiring imputations in some but
not all sub-samples. Another situation is when in silico replications
are performed for candidate or genome-wide association analyses.
In this case, statistically significant SNPs are genotyped in the
discovery sample, and may not be genotyped in all the replication
samples and thus need to be imputed, such as in our previous
study [19].
Both risk increasing allele frequency and the magnitude of
variation explained by the causal SNPs can affect between-study
heterogeneity, as shown in Fig. 1. Briefly, for a specific value of var,
an increasing RAF results in less between-study heterogeneity; and
for a specific range of RAF, an increasing value of var results in
more between-study heterogeneity. These trends may be partially
explained by effect sizes of the causal SNPs. On one hand, greater
effect sizes may imply greater between-population variation for the
causal SNPs, and thus greater chances for observing between-
study heterogeneity. On the other hand, it is known from
population genetics theory that the variation explained by the
causal SNPs is proportional to RAF*(1-RAF)*a
2, where a is the
effect size for the causal SNP. Thus for a fixed value of var,a n
Table 3. Mean power and type-I error rate of Zmeta (a=10
27).
QTL variance (%) Fixed-effects model Random-effects model
RAF1 RAF2 RAF3 RAF4 RAF1 RAF2 RAF3 RAF4
Scenario 1 0 3.01 2.98 3.10 2.97 2.86 3.05 2.89 2.89
0.5 18.77 20.93 19.38 19.41 16.35 20.93 19.34 19.40
1.0 84.96 82.32 81.66 80.43 78.39 81.81 81.36 80.23
1.5 98.79 97.76 95.69 95.90 93.24 94.66 93.89 92.29
2.0 100.00 98.88 96.69 96.72 96.17 95.77 95.59 95.09
Scenario 2 0 3.27 3.33 3.25 3.42 3.13 3.12 3.04 3.05
0.5 17.20 14.01 13.71 8.91 17.20 14.01 13.60 7.72
1.0 69.90 67.77 56.32 49.29 69.90 67.77 56.00 44.66
1.5 88.20 84.35 81.19 68.76 88.09 84.35 80.77 62.83
2.0 91.51 90.22 86.61 73.87 91.29 90.11 85.87 66.15
Scenario 3 0 5.57 5.49 5.48 5.50 3.55 3.52 3.53 3.52
0.5 10.13 7.42 7.65 4.04 10.92 8.14 7.65 5.70
1.0 37.26 34.81 29.76 26.48 38.18 37.70 36.69 33.27
1.5 46.98 44.8 41.34 34.92 46.08 47.14 46.09 42.62
2.0 49.13 47.27 44.00 38.12 53.33 52.54 51.26 49.17
Scenario 4 0 5.56 5.53 5.52 5.56 3.54 3.53 3.56 3.54
0.5 8.60 7.55 7.21 4.40 8.72 7.83 7.61 4.99
1.0 32.77 35.02 35.02 31.12 33.25 32.41 32.12 30.22
1.5 45.27 45.73 45.73 39.61 46.76 46.34 45.01 40.63
2.0 47.50 47.89 47.89 40.94 51.43 50.20 49.74 45.55
Descriptions for Scenarios 1–4 and RAF ranges are given in Table 2. Mean power and type-I error rates were estimated based on 1,000 simulations.
doi:10.1371/journal.pone.0034486.t003
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of RAF, an increasing var yields a greater value for a. For either
case, the magnitudes of effect sizes are positively correlated with
those of between-study heterogeneity.
To deal with the negative impacts of genotype imputation on
meta-analysis of GWAS, we provide the following suggestions
based on our study. Firstly, focus on SNPs presented in all
individual studies, as meta-analysis with direct genotypes in all
individual studies help to avoid generating spurious between-study
heterogeneity by genotype imputation. Secondly, random-effects
model should be used when significant between-study heteroge-
neity is detected. Although the random-effects model may not
guarantee higher power than that of the fixed-effects model, it may
help obtain more accurate effect size estimation. Thirdly, when
sample sizes of individual studies vary largely, the results from the
largest individual sample should be carefully evaluated, as it may
provide better power than that of mate-analysis with imputation.
Lastly, improving imputation accuracy may be useful in reducing
between-study heterogeneity introduced by genotype imputation.
A number of issues in our studies may need further investigations.
For example, only three GWAS sub-samples were used in our
current study. Although a similar number of individual populations
were used in various published meta-analysis of GWAS (e.g.,
[14,20]), increasing the number of sub-samples in simulation studies
may be needed in order to provide more robust conclusions. In our
simulations, all sub-samples are constructed from the same
genotyping platform. Additional simulations may be helpful in
understanding the power for meta-analysis of GWAS using samples
with different genotypes. Thus in future studies, we will perform
analyses to investigate situations such as increased numbers of sub-
samples and sub-samples with different genotyping platforms.
Materials and Methods
In this section, we will first summarize how the sub-populations
are constructed; we then describe the model and procedure for
phenotype simulation; and at the end, we describe several topics
related to our analyses, including imputation method, analytical
models and test statistic for meta-analysis, and heterogeneity
detection.
Sub-population construction
The individual study samples used for the meta-analysis were
constructed from an empirical GWAS dataset, the genome-wide
genotyping data obtained from FHS SNP Health Association
Resource (SHARe) project. The application for using the data has
been approved by Tulane University Institutional Review Board and
the access to the data has been granted by NHLBI Data Access
Committee. The dataset containsmore than 9,300 subjects from three
generations of over 900 families and was genotyped for ,550,000
SNPs (Affymetrix 500 K mapping arrays plus Affymetrix 50 K
supplemental arrays). Detailed information about the FHS and its
genotyping dataset can be found at the dbGaP website. For simplicity,
we only used the SNPs in the 500 K array for subsequent analyses.
To imitate meta-analysis, three sub-samples (Samples 1–3) were
constructed, with related information summarized in Table 1.
Briefly, Sample 1 included all unrelated subjects from the 1
st
generation (two at most in each pedigree), and married-ins in the
2
nd and 3
rd generations. Sample 2 and Sample 3 were constructed
by randomly selecting one subject from the rest members of the
2
nd and 3
rd generations in each pedigree, respectively. This
selection strategy helps to ensure unrelatedness among individuals
within each sample. After data quality controls, including
removing individuals with genome-wide genotype missing rates
.10%, SNPs with genotyping call rates ,90% or minor allele
frequencies ,0.01, and Hardy-Weinberg equilibrium test p-
values,=0.0001, the numbers of individuals for Samples 1–3
are, respectively, 2,023 (883 males and 1,140 females), 1,055 (471
males and 584 females), and 806 (362 males, 444 females), and the
number of common SNPs across all three populations is 392,261.
Notice that throughout the simulations, genotypes were fixed and
obtained from the FHS data set directly, and phenotypes were
simulated as described in the next session.
Genotypes of three independent populations were also gener-
ated through simulations using the software HAPGEN2. The
sample sizes for the three populations were 2000, 1000, and 1000,
respectively. The genotypes were generated based on the 1000
Genomes data provided by the software, and SNPs matching those
in the Affymetrix 500 K mapping array were then selected to be
the genotyped SNPs for the simulated populations. This simulation
produced fully independent samples.
Phenotype simulation
For a di-allelic quantitative trait locus (QTL), the risk allele and
the alternative allele are denoted by 1 and 0, respectively. The
Figure 2. Comparison of effect size and standard error
estimated by meta-analysis to simulated true values. The
simulated QTLs explain 2.0% of the total trait variance.
doi:10.1371/journal.pone.0034486.g002
Figure 3. Power comparison between meta-analysis of differ-
ent scenarios and association analysis in individual Sample 1.
Sample1_geno and Sample1_impu refer to situations where causal
SNPs are typed and imputed, respectively, in Sample 1. QTL variation of
2.0% is used.
doi:10.1371/journal.pone.0034486.g003
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respectively. With an additive genetic effect of a, the phenotypic
value for the ith individual is modeled by: ^ y yi~mz^ b bgize, where m
is the mean population phenotypic value, gi is the genotype score
which is coded as the number of risk alleles carried by the ith
individual, ^ b b is the regression coefficient rendering the effect of the
assessing QTL (E(^ b b)~a), and e represents the residual error. The
variance due to the QTL is then var or s2
a~2pqa2.
To cover various biologically plausible conditions, our analyses
were performed with a range of parameter values. Briefly, the
variance explained by an assumed QTL was set as 0–2.0% with a
0.5% increment. Risk increasing allele frequency (RAF) was
binned into four intervals: 0.01,RAF#0.05, 0.05,RAF#0.10,
0.10,RAF#0.20 and 0.20,RAF#0.50, which were represented
by RAF1-4, respectively. To simulate meta-analysis with or
without genotype imputation in individual studies, four scenarios
(listed in Table 2) were considered: 1) causal SNPs were directly
typed in all sub-samples; 2) causal SNPs were imputed in all sub-
samples; 3) causal SNPs were imputed in Samples 1 & 2 and typed
in Sample 3; and 4) causal SNPs were imputed in Sample 1 and
genotyped in Samples 2 & 3.
The simulation process for phenotypic values follows the
strategy proposed by Anderson et al [21]. Briefly, for each
combination of parameter values, one SNP at each time was
randomly picked as a causal variant from the genome-wide data
set, and the phenotypic values were then simulated for the study
subjects according to their genotypes for the SNP. The selected
SNP was then set as directly typed or untyped. Power and type-I
error were estimated as the proportions of significant simulation
replicates with an assumed genome-wide significance level of 10
27
and an additive model. For each combination of RAF range and
QTL variance, 1,000 simulations were performed.
Genotype imputation and genetic association analysis in
individual studies
Untyped SNPs were imputed by the program IMPUTE
(Version 0.5.0) [16] using default parameters. Based on the
hidden Markov Model and conditional on a set of known
haplotypes and an estimated fine-scale recombination map, the
program produces the probability distribution of missing geno-
types. The phased HapMap II (rel#22 - NCBI Build 36) genotype
data from the 60 CEU HapMap founders was used as the
reference set. The minimum posterior probability of 0.95 was used
as the threshold to accept the imputed genotypes as accurate for
association tests [22].
SNP association tests were carried out by using the program
SNPTEST (Version 1.5.1) [16], which implements an F-test and
accounts for the uncertainty in the imputed genotypes.
Meta-analysis
Fixed-effects and random-effects models. Fixed-effects
model considers the genetic effects to be the same across all
individual studies and assumes that any difference is due to
chance. In genetic association studies, however, genetic effects
could be different across populations due to various reasons such
as allele frequency differences, different biases and estimation
errors across studies. Thus to take these differences into
consideration, random-effects model may be a better choice, as
random-effects model assumes and can accommodate the
potential differential effects across studies.
Test statistic for meta-analysis. In this study, we adopted
the inverse variance method to construct the test statistic for meta-
analysis, which was recently reviewed in the context of genetic
association for quantitative traits by de Bakker and colleagues [5].
The test statistic takes the following form,
Zmeta~
^ b b
SE
ð1Þ
where ^ b b~
P
i biwi P
i wi
, SE~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 P
i wi
r
, wi~ 1
SE2
i zt2. For fixed-effects
model, t2~0, and for random-effects model, t2 is a function of
Cochran’s Q (see below). bi and SEi denote the beta coefficient
and standard error of the estimated genetic effect in the ith study,
respectively. The test statistic Zmeta approximately follows a
standard normal distribution, which is the basis for assessing its
statistical significance.
Heterogeneity measurements. To test between-study
heterogeneity, we used the I
2 index [6], which is
I2~
Q{(k{1)
Q , Qw(k{1)
0, Qƒ(k{1)
(
ð2Þ
where k is the number of studies and Q represents Cochran’s Q
statistic [23], defined as
Q~
X
i
wi(Ti{^ T T) ð3Þ
where Ti and ^ T T are effect sizes for the ith study and the combined
study, respectively.
The I2 index, taking values between 0–100 percent, can be
interpreted as a percentage of heterogeneity, that is, the part of
total variation that is due to between-study variance. This statistic
is independent of the number of studies and can be compared
across meta-analyses with different number of studies and metrics.
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